Biogen (BIIB) Tops Q3 EPS by 22c
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $199.71 +1.59%
Revenue Growth %: -6.5%
Financial Fact:
Net income: 1.03B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -6.5%
Financial Fact:
Net income: 1.03B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q3 EPS of $5.19, $0.22 better than the analyst estimate of $4.97. Revenue for the quarter came in at $2.96 billion versus the consensus estimate of $2.91 billion.
Eloctate revenue $131.8 million, est. $131.2 million.
Alprolix revenue $85.2 million, est. $86.2 million.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- AXT appoints Tracy Liu to its board of directors
- JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
Create E-mail Alert Related Categories
Earnings, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
